ELAN · CIK 1739104
What Elanco Animal Health Incorporated told the SEC could break it.
Elanco's disclosures combine customer, regulatory and supply exposures of an animal-health company. Its revenue is concentrated in distributors — its largest, a Cencora affiliate, was about 12% of 2025 revenue and its second roughly 7%, together about 19% — so losing a key distributor would hurt sales. A meaningful slice of its business is also exposed to antibiotic policy: shared-class antibiotics were 9% and animal-only antibiotics 15% of 2025 revenue, and bans like the one Vietnam implemented in January 2026 could reduce those sales elsewhere. On the supply side, while it dual-sources key active ingredients for its top brands, it gets certain raw materials or API from a single source and leans on roughly 140 contract manufacturers, where a disruption could interrupt supply.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- two third-party distributors = ~19% of revenue (Cencora affiliate 12%, second 7%)medium
Elanco's revenue is concentrated in distributors — its largest customer (a Cencora affiliate) was ~12% of 2025 revenue and its second largest (also a distributor) ~7%, together ~19%; no other customer exceeded 5%, so loss of a key distributor would materially affect sales.
“We have a single customer that accounted for approximately 12 % , 11 % and 10 % of revenue for the years ended December 31, 2025, 2024 and 2023, respectively. Product sales with this customer resulted in accounts receivable of $ 107 million and $ 90 million as of December 31, 2025 and 2024, respectively.”
SEC filing →As of 2026
Regulatory & policy
- antibiotic bans/restrictions (Vietnam Jan 2026) on animal antibioticsmedium
Government bans/restrictions on animal antibiotics threaten a meaningful revenue slice — shared-class antibiotics were 9% and animal-only antibiotics 15% of Elanco's 2025 revenue; a ban was implemented in Vietnam in January 2026, and similar bans elsewhere could materially reduce antibiotic-product sales.
“Further, a similar ban was also recently implemented in Vietnam in January 2026. Similar bans and restrictions in other countries could result in a material adverse effect on our sales of antibiotic products... our revenue from shared-class antibiotics represented 9% of total revenue, while our revenue from animal-only antibiotics represented 15% of total revenue.”
SEC filing →As of 2026
Sole-source dependency
- single-source raw materials/API for certain inputs; ~140 CMOsmedium
Elanco generally maintains dual sources for key API of its highest-value brands, but in some instances obtains certain raw/intermediate materials or API from only a single source, and supplements its 16 internal manufacturing sites with ~140 CMOs; supplier disruption can interrupt supply until new sources/processes/facilities are established.
“For key API supporting our highest value brands, we generally maintain dual sources. In some instances, we may obtain certain raw or intermediate materials and API from only a single source; however, we utilize inventory management strategies to enable reliable supply.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Our largest customer, an affiliate of Cencora, Inc., is a third-party veterinary distributor and represented approximately 12% of our total revenue in 2025.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch